![Elise Chemin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mrs. Elise Chemin began her professional career in 2004 in the Equity Capital Markets department of Calyon, then in the European Strategy department of General Motors in Germany.
In 2005, she joined Société Générale in the Leverage Finance team.
She participated in a number of transactions including the buy-outs of RLD or Histoire d’Or, for French as well as international sponsors.
Mrs. Chemin is a graduate of ESCP-EAP, where she majored in Finance.
Tidigare kända positioner av Elise Chemin
| Företag | Position | Slut |
|---|---|---|
Weinberg Capital Partners SAS
 Weinberg Capital Partners SAS Investment ManagersFinance WCP invests in small and middle capital companies located in France with an EBITDA of more than EUR 2 million and enterprise value of EUR 30 - 250 million. The firm targets companies operating in the fields of cosmetics and services in B2B & B2C. It participates in growth and LBO transactions with an investment size of EUR 5 - 20 million. The firm takes minority and majority interests. It also makes co-investments. | Private Equity-analytiker | 2012-04-01 |
Mutabilis SA
 Mutabilis SA Pharmaceuticals: MajorHealth Technology Develops antibiotics and antibacterial therapies | Direktör/Styrelseledamot | - |
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
12
Första gradens relationer
2
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 2 |
|---|---|
Mutabilis SA
Mutabilis SA Pharmaceuticals: MajorHealth Technology Develops antibiotics and antibacterial therapies | Health Technology |
Weinberg Capital Partners SAS
Weinberg Capital Partners SAS Investment ManagersFinance WCP invests in small and middle capital companies located in France with an EBITDA of more than EUR 2 million and enterprise value of EUR 30 - 250 million. The firm targets companies operating in the fields of cosmetics and services in B2B & B2C. It participates in growth and LBO transactions with an investment size of EUR 5 - 20 million. The firm takes minority and majority interests. It also makes co-investments. | Finance |
